Over dinner in Davos, the CEOs of Novartis, Coca-Cola, and Grab shared what’s worrying them
- ByFortune-
Highlights from Fortune's dinner in Davos.
Highlights from Fortune's dinner in Davos.
By Ludwig Burger BASEL (Reuters) - Novartis on Wednesday predicted that core operating income would grow in a "mid single digit" percentage range in 2023 following stagnation last...
By Geoffrey Smith Investing.com -- The Fed is set to raise interest rates by another 25 basis points, with all eyes on how chair Jerome Powell responds later to speculation on a...
Inflation worries continue to weigh on equity markets Earnings season will likely increase volatility ETFs offer investors ability to diversify Earnings season has started with...
The big pharmaceutical companies have always tended to generate a somewhat mixed response when discussed in the wider context of stock picking. The sector has had a fairly...
The big pharmaceutical companies have always tended to generate a somewhat mixed response when discussed in the wider context of stock picking. The sector has had a fairly...
Novartis AG researches, develops, manufactures, and markets healthcare products in Switzerland and internationally. The company operates through two segments: Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and physicians. It also provides cardiovascular, ophthalmology, neuroscience, immunology, hematology, and solid tumor products. The Sandoz segment develops, manufactures, and markets finished dosage forms of small molecule pharmaceuticals to third parties. It also provides protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services; and anti-infectives, such as active pharmaceutical ingredients and intermediates primarily antibiotics. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
| Average | 104.25 (+20.74% Upside) |
| High | 107.00 |
| Low | 102.00 |
| Price | 86.34 |
| No. of Analysts | 4 |
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Buy | Buy | Neutral | Sell | Buy |
| Technical Indicators | Neutral | Strong Buy | Strong Buy | Strong Sell | Strong Buy |
| Summary | Neutral | Strong Buy | Buy | Strong Sell | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 19.36 | 20.15 | 19.28 | -0.36 | -1.83% | 4.79M | London | |||
| 243.70 | 243.70 | 231.70 | +11.70 | +5.04% | 4.15M | London | |||
| 516.40 | 516.40 | 488.00 | +38.05 | +7.95% | 84.50M | London | |||
| 1,012.00 | 1,028.00 | 1,007.00 | -14.00 | -1.36% | 1.11M | London | |||
| 158.00 | 158.00 | 158.00 | +7.00 | +4.64% | 45.94K | London | |||
| 431.50 | 445.00 | 431.00 | -5.5 | -1.26% | 183.38K | London | |||
| 1.10 | 1.10 | 1.10 | -0.025 | -2.22% | 1.96M | London | |||
| 330.60 | 337.40 | 324.20 | +2.00 | +0.61% | 864.29K | London | |||
| 115.00 | 116.50 | 114.00 | 0.00 | 0.00% | 0.00 | London | |||
| 333.30 | 336.25 | 329.55 | +2.65 | +0.80% | 10.69M | London | |||
| 117.20 | 125.00 | 116.40 | -6.20 | -5.02% | 336.10K | London | |||
| 42.00 | 43.80 | 42.00 | +1.70 | +4.22% | 1.00M | London | |||
| 14.75 | 14.90 | 14.51 | 0.00 | 0.00% | 35.70K | Aquis Exchange | |||
| 5,754.00 | 5,790.00 | 5,718.00 | -30.0 | -0.52% | 903.73K | London | |||
| 62.95 | 65.75 | 62.05 | -1.05 | -1.64% | 38.37K | London |